LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Autoantibody Test Helps Diagnose Type 1 Diabetes

By LabMedica International staff writers
Posted on 09 Sep 2014
Print article
Image: The Zinc Transporter 8 Autoantibody (ZnT8Ab) enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of KRONUS).
Image: The Zinc Transporter 8 Autoantibody (ZnT8Ab) enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of KRONUS).
The first zinc transporter 8 autoantibody (ZnT8Ab) test has been approved for marketing and the test can help determine if a person has diabetes mellitus type 1 and not another type of diabetes.

Type 1 diabetes is the most common type of diabetes diagnosed in children and adolescents, but in some instances it may also develop in adults and people with the disease produce little or no insulin because their immune system attacks and destroys the cells in the pancreas that produce insulin.

The Food and Drug Administration (FDA; Silver Spring, MD, USA) has allowed marketing by review through the de novo premarket review pathway, a regulatory pathway for some low- to moderate-risk medical devices that are not substantially equivalent to an already legally marketed device.

The FDA reviewed data from a clinical study of 569 blood samples, 323 from patients with diagnosed type 1 diabetes and 246 samples from patients diagnosed with other kinds of diabetes, other autoimmune diseases, and other clinical conditions. The test was able to detect the ZnT8 autoantibody in 65% of the samples from patients with diagnosed type 1 diabetes and incorrectly gave a positive result in less than 2% of the samples from patients diagnosed with other disease. The Zinc Transporter 8 Autoantibody (ZnT8Ab) enzyme-linked immunosorbent assay (ELISA) Assay is manufactured by KRONUS Inc. (Star, ID, USA).

Alberto Gutierrez, PhD, the director of the Office of In Vitro Diagnostics and Radiological Health in the Center for Devices and Radiological Health at the FDA, said, “Early treatment of type 1 diabetes is important in helping to prevent further deterioration of insulin producing cells. This test can help patients get a timely diagnosis and help start the right treatment sooner." A negative result from the test does not rule out a diagnosis of type 1 diabetes. The test should not be used to monitor the stage of disease or the response to treatment.

Related Links:

US Food and Drug Administration 
KRONUS Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more